- Zoetis is seeking court order blocking Dechra from making its product until patent has expired and cash compensation if it’s made before then, according to
complaint filed Friday in federal court in Wilmington, Delaware - Patent is titled “Antimicrobial Preservatives to Achieve Multi-dose Formulation Using Beta-Cyclodextrins for Liquid Dosage Forms,” complaint says, and expires in January 2027:
supplemental filing - Patent for Cerenia’s active ingredient, maropitant, has expired, but “formulation patents ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.